Melanomas are very aggressive neoplasms with notorious resistance to therapeutics. It was recently proposed that the remarkable phenotypic plasticity of melanoma cells allows for the rapid development of both resistance to chemotherapeutic drugs and invasive properties. Indeed, the capacity of melanoma cells to form distant metastases is the main cause of mortality in melanoma patients. Therefore, the identification of the mechanism controlling melanoma phenotype is of paramount importance. In the present report, we show that deletion of microphthalmiaassociated transcription factor (MITF), the master gene in melanocyte differentiation, is sufficient to increase the metastatic potential of mouse and human melanoma cells. MITF silencing also increases fibronectin and Snail, two mesenchymal markers that might explain the increased invasiveness in vitro and in vivo. Furthermore, ablation of this population by Forskolin-induced differentiation or MITF-forced expression significantly decreases tumour and metastasis formation, suggesting that eradication of low-MITF cells might improve melanoma treatment. Moreover, we demonstrate that a hypoxic microenvironment decreases MITF expression through an indirect, hypoxia-inducible factor 1 (HIF1)a-dependant transcriptional mechanism, and increases the tumourigenic and metastatic properties of melanoma cells. We identified Bhlhb2, a new factor in melanoma biology, as the mediator of hypoxia/HIF1a inhibitory effect on MITF expression. Our results reveal a hypoxia-HIF1a-BHLHB2-MITF cascade controlling the phenotypic plasticity in melanoma cells and favouring metastasis development. Targeting this pathway might be helpful in the design of new anti-melanoma therapies.
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Introduction
Although melanoma is a relatively rare cancer, it is the leading cause of death from skin cancer, and its incidence continues to increase in the Caucasian population. If diagnosed early, a large surgical resection is generally sufficient to cure more than 90% of melanoma. However, if the primary lesion is too thick (44 mm) or if melanoma cells have metastasised to regional lymph nodes or to distant organs, the prognosis is extremely pejorative, because existing anti-melanoma therapeutic regiments have a very low survival rate. The notorious aggressiveness of melanoma is due to its remarkable metastatic propensity. Strikingly, metastatic dissemination from small primary lesions (less than 1 mm) is not an exceptional clinical event (Shaw et al., 1987; Bedrosian et al., 2000; Corsetti et al., 2000) . These observations suggest that melanomas acquire their invasive and metastatic behaviours very early and without the absolute necessity to accumulate additional oncogenic mutations favouring distant tumour development. In fact, it has been proposed that melanoma cells intrinsically possess a genetic programme predisposing them to exacerbated metastatic features (Gupta et al., 2005) . The same programme is implemented by melanocyte precursors during their differentiation process to allow their migration from neural crest to skin during embryonic development.
As is the case for many other neoplasms, physiological differentiation of melanocytes and metastatic melanoma development share common signalling pathways, such as ERK and PI3 kinase pathways (Busca and Ballotti, 2000) . However, the most remarkable connection between these two processes is the microphthalmiaassociated transcription factor (MITF). Indeed, MITF was identified as the master gene in melanocyte differentiation, which it does by controlling the expression of melanogenic enzymes (TYR, TYRP1, DCT). Later, MITF was shown to regulate the expression of genes involved in all steps of melanocyte differentiation, including dendricity (DIA), melanosome biogenesis (SILVER, OA1) and melanosome transport (RAB27a) (for review, see Cheli et al. (2010) ). Concomitantly, King et al. (2001) reported that MITF expression was maintained in more than 85% of melanoma, and a MITF gene amplification has been found in more than 20% of metastatic melanomas. MITF was shown to control the expression of genes involved in cell survival (BCL2, BIRC7) and in cell cycle control (CDK2; Cheli et al., 2010) . Moreover, MITF silencing blocked melanoma cells in G0/G1 (Du et al., 2004; Carreira et al., 2006) and induced senescence (Giuliano et al., 2010) . Taken together, these observations provide compelling support for a key role of MITF in favouring melanoma development.
Remarkably, most primary melanomas and skin metastases are heavily pigmented. Furthermore, Silver and MART1, two melanoma differentiation markers, are used by the pathologists to identify melanoma lesions. Therefore, in agreement with persistent MITF expression, melanomas frequently appear to be committed to the differentiation process.
However, this new dogma qualifying MITF, the first melanocyte differentiation marker, as a melanocyte lineage-restricted oncogene is somehow paradoxical to an older and more universal doctrine stipulating that tumour differentiation is inversely correlated with its aggressiveness. It should be mentioned that several reports suggest that MITF might have an anti-melanoma activity. Indeed, MITF overexpression prevented xenograft tumour development (Carreira et al., 2006; Cheli et al., 2011) . It was also reported that MITF upregulated the expression of two cyclin kinase inhibitors, CDKN2A (Loercher et al., 2005) and CDKN1A (Carreira et al., 2005) , and MITF depletion was demonstrated to increase melanoma cell migration in vitro (Carreira et al., 2006) .
To reconcile these apparently contradictory sets of data, a pertinent and elegant model was proposed (Carreira et al., 2006) in which MITF would function as a rheostat to control melanoma cell phenotype and behaviour, allowing a reversible switch from poorly differentiated and highly metastatic cells to fast growing progeny. This model was validated by our recent data (Cheli et al., 2011) demonstrating that a transiently slow growing and MITF-low population existed in melanoma cell lines and in melanoma cells, freshly isolated from human biopsy specimens. This MITF-low population has exacerbated tumourigenic properties, whereas the MITF-high population grew faster, but displayed poor tumourigenicity when injected in mice.
In the present study, we show that MITF silencing increased the invasive and metastatic properties of melanoma cells. Furthermore, we demonstrate that hypoxia inhibits MITF expression and increases the tumourigenic and metastatic potential of melanoma cells. Taken together, our results indicate that the downregulation of MITF by hypoxia is a key molecular event that controls the metastatic properties of melanoma cells. In contrast with the dogma ascribing oncogenic activity to MITF and suggesting that inhibition of MITF is a promising way to cure melanoma, our data show that inhibition of MITF favours tumour and metastasis development and might be deleterious in melanoma treatment.
Results

MITF silencing exacerbates the metastatic properties in B16 melanoma cells
We previously showed that injection of MITF-silenced B16 cells in syngeneic mice (C57bl6) gave rise to larger tumours compared with cells transfected with scrambled small interfering RNA, indicating that MITF silencing increases the tumourigenic potential of melanoma cells (Cheli et al., 2011) . However, the real clinical burden of melanomas is due to their elevated metastatic potential. Therefore, we studied the effect of MITF depletion on the metastatic behaviours of B16 melanoma cells.
First, we showed by fluorescence-activated cell sorting analysis and western blot (Figures 1a and b ) that siMITF transfection in B16F10 melanoma cells led to an almost complete loss of MITF. Then, as previously shown in human melanoma cells 501Mel and SKMel28 (Carreira et al., 2006) , MITF depletion increased both the migration and the invasion properties of B16 melanoma cells in vitro. Taken together the above observations suggest that MITF silencing might favour metastasis development in vivo, but this hypothesis has never been demonstrated. To verify this hypothesis, lung colonisation and visceral metastasis were analysed after injection in the tail vein of C57bl6 mice of increasing number of siScrambled-or siMITF-transfected B16 cells. Notably, we observed no increase in lung melanoma tumour development in mice injected with 0.25 Â 10 6 MITF-depleted B16 cells. However, after injection of lower number of cells, we observed that the siMITF-transfected B16 cells gave rise to a larger number of lung tumour. The number of visceral metastases (ovaries, kidneys, intestine and heart) significantly increased in mice that received siMITFtransfected B16 cells, regardless the number of injected cells (Figure 1d ). Histological analysis of these metastases after haematoxylin and eosin staining showed that in tumours, arising from siMITF-transfected cells, there was a larger haemorrhagic area, with a presence of necrotic cells and a small islet of normal cells around the vessels. Higher magnification showed hyperchromatic nuclei with a low mitotic rate in control metastases. In siMITF metastases, we observed clear nuclei, with inconspicuous nucleoli and numerous mitotic figures (Figure 1e ). Therefore, MITF depletion exacerbates the metastatic behaviour of B16 melanoma cells in vivo.
MITF silencing favours the mesenchymal phenotype in B16 melanoma cells Cell motility and metastasis are positively correlated with the mesenchymal phenotype (Radisky, 2005; Alonso et al., 2007) . Therefore, we next examined the effect of MITF on mesenchymal markers. Quantitative PCR on MITF-depleted cells showed a two-to threefold increase in Snai1, Fn1 and Sparc expression. However, we observed a decrease in Snai2 expression (Figure 2a) . Western blotting confirmed the increase in Snai1, Fn1 and Sparc expression at the protein level (Figure 2b) . Consistently, Snai2 protein expression was inhibited in MITF-silenced cells. Of note, Fn1 and Sparc levels were also increased in the cell culture medium (Figure 2c ), indicating that these proteins are correctly processed and secreted. MITF silencing increases the mesenchymal phenotype in B16 melanoma cells.
Pharmacological depletion of the MITF-negative population in mouse melanoma cells inhibits tumour and metastasis development Interestingly, a MITF-negative population (ranging from 1 to 2.5%) exists spontaneously in B16 melanoma cell lines as shown by fluorescence-activated cell sorting analysis ( Figure 3a) . Therefore, we asked whether forced melanoma cell differentiation by Forskolin treatment would ablate the MITF-low population and impair tumour and metastasis development. Treatment of B16 melanoma cells with Forskolin for 48 h led to a depletion of the MITF-low population ( Figure 3a ). Note that the global level of MITF did not change after 48 h of Forskolin treatment. This is in agreement with a previous report (Bertolotto et al., 1998) demonstrating that a cAMP-elevating agent induced a transient increase in MITF expression that returned to the basal level after 48 h. When B16 cells were injected into Forskolin-treated mice, subcutaneous tumours developed more slowly (Figure 3b ). Furthermore, after injection in the tail vein, we observed a decrease in lung tumours and fewer visceral metastases in Forskolintreated mice (Figures 3c and d) .
Analysis of tumour cells showed a modest global increase in MITF expression and a significant decrease in the MITF-negative population in the tumours from mice treated with Forskolin ( Supplementary Figure 1) . Of note, adenovirus-driven MITF overexpression ( Figure 3e ) was sufficient to decrease the tumour volume after subcutaneous injection (Figure 3f ). Collectively, these results demonstrate that the level of MITF is a key parameter in determining the tumourigenic and metastatic properties of B16 melanoma cells. The low-MITF population displays exacerbated metastatic behaviours.
MITF regulates mesenchymal phenotype and invasiveness in human melanoma cells
We determined whether MITF silencing induced a mesenchymal phenotype and increased the metastatic potential in the MeWo human melanoma cells. MITF depletion increased mesenchymal markers, such as FN1, SPARC, SNAI1, at the protein level, whereas SNAI2 was inhibited (Supplementary Figure 2A) . Moreover, MITF silencing increased lung colonisation Figure 2B) , when injected in the tail vein.
Next, we observed that Forskolin was also able to deplete the MITF-low population in the MeWo cells after 48 h of treatment (Supplementary Figure 2C) . In addition, Forskolin treatment of nude mice injected with MeWo cells led to a significant decrease in subcutaneous tumour volume (Supplementary Figure 2D) and metastasis number (Supplementary Figure 2E) . Overexpression of MITF in MeWo cells (Supplementary Figure 2F , left panel) also drastically inhibited formation of tumours after injection in nude mice (Supplementary Figure 2F , right panel). Taken together, these data demonstrated that loss of MITF leads to a mesenchymal phenotype and increases the metastatic potential in human melanoma cells.
Hypoxic conditions induce a loss of MITF It has been reported that hypoxia is an essential cofactor for melanoma development (Bedogni et al., 2005) . Therefore, we studied the effect of a hypoxic challenge on MITF expression, and on the metastatic potential of melanoma cells. Upon exposure of B16, SkMel-28 and Mewo cells to a hypoxic environment (1% oxygen), we observed an increase in hypoxia-inducible factor 1 (HIF1)a expression; whereas, MITF expression decreased markedly in the three cell lines (Figure 4a ). MITF decrease was also observed upon treatment with cobalt, a hypoxia mimetic that inhibits proline hydroxylase and consequently increases HIF1a expression (Figure 4b ). These results allow us to conclude that hypoxic conditions repress MITF expression in melanoma cells. Next, we checked whether MITF regulation under hypoxia was due to transcriptional regulation. Treatment with cobalt led to a 60% decrease in the transcriptional activity of a 2-kb fragment of the MITF promoter (p-MITF; Figure 4c ). Forskolin induced a twofold increase in the transcriptional activity of this fragment. Then, using two shorter promoter fragments, p-MITF D1 (1.5 kb) and p-MITF D2 (1.1 kb), we observed that these fragments were still stimulated by Forskolin but failed to respond to hypoxia-mimetic treatment. These data indicate that a hypoxia-responsive element is located in the p-MITF between À1.5 and À2 kb (downstream transcription start site).
As HIF1a has a pivotal role in the transcriptional response to hypoxia, we checked whether the decrease in p-MITF activity was mediated by HIF1a. First, we observed that HIF1a silencing prevented the inhibition of the p-MITF and the activation of the pHRE by cobalt treatment, indicating that the inhibition of MITF transcription upon hypoxia is dependant on HIF1a (Figure 4d ). However, when we co-transfected p-MITF, Hypoxia controls MITF and invasiveness in melanoma cells Y Cheli et al with a stabilised HIF1a mutant, the p-MITF activity was not affected by HIF1a overexpression, whereas p-HRE activity was clearly stimulated. Taken together, these data indicate that MITF downregulation under hypoxia is dependant on HIF1a, but that HIF1a does not directly regulate the p-MITF. To confirm that HIF1a is not a direct regulator of p-MITF, we performed a chromatin immunoprecipitation (ChIP) assay and PCR amplification with specific primers of the p-MITF, on total DNA extract or after immunoprecipitation with antibody to polymerase II, as a positive control, we amplified a 370-bp fragment (Supplementary Figure 3) . After immunoprecipitation with anti-HIF1a, no band was amplified under normal oxygen or hypoxia conditions. Conversely, using specific erythropoietin promoter primers (Supplementary Figure 3 , lower panel), we amplified 700-bp fragment corresponding to the erythropoietin promoter in the total extract, the anti-Pol II precipitates, and only under hypoxia condition after immunoprecipitation with anti-HIF1a antibody. These results confirm that HIF1a does not bind to the p-MITF.
Furthermore, we performed immunostaining of human tumour samples for MITF and HIF1a (Supplementary Figure 4 ). We observed no HIF1a expression in the close vicinity of the vessels. HIF1a labelling increased with distance from the blood vessels. Conversely, MITF labelling was strong around the vessels and decreased in the remote regions, supposed to be hypoxic. These observations indicate that in some tumour regions, an inverse correlation between MITF and HIF1a can be observed, in agreement with a regulation of MITF expression, in vivo, by hypoxia and HIF1a.
Bhlhb2 is induced by hypoxia and represses MITF expression Transcription factors Bhlhb2, Sap30, Atf3 and Mxi1 were reported to be regulated upon exposure of B16 melanoma cells to hypoxic conditions (Olbryt et al., 2006) . Therefore, we examined the effect of cobalt or hypoxia on these transcription factors. Quantitative PCR showed a consistent threefold increase in Bhlhb2 expression by hypoxia (Figure 5a ) or cobalt (Figure 5b ). Sap30 was slightly upregulated by hypoxia, but not by cobalt, whereas Atf3 was strongly stimulated upon cobalt treatment, but not by hypoxia. No significant regulation of Mxi1 was observed in both conditions. Therefore, we focused our attention on the role of Bhlhb2 in the regulation MITF under hypoxia conditions. Quantitative PCR analysis on siBhlhb2-transfected cells showed a strong inhibition of the Bhlhb2 messengers that led to an increase in MITF expression and prevented the downregulation of MITF expression under hypoxia conditions (Figure 5c ). Knockdown of Bhlhb2 under hypoxia rescued p-MITF activity (Figure 5d ). Chromatin immunoprecipitation assay, with antibody to Bhlhb2 showed the binding of this transcription factor to the p-MITF (Supplementary Figure 5A) , and Bhlhb2 overexpression repressed the p-MITF activity (Supplementary Figure 5B) .
We also checked for Brn-2, as it was reported to repress MITF expression. Brn-2 was not affected by cobalt and was slightly downregulated by hypoxia (Supplementary Figure 6) in B16 cells. This observation is in agreement with our previous report demonstrating that BRN2 was not increased in the MITF-negative population (Cheli et al., 2011) . We also observed that Atf3 silencing (Supplementary Figure 7A) did not prevent the inhibition of the p-MITF activity induced by cobalt (Supplementary Figure 7B) . Taken together, these data show that the increase in Bhlhb2 expression under hypoxia is responsible for the decrease of MITF in melanoma cells. . Cells were either then exposed to 200 mM CoCl 2 or were not exposed, for 24 h, and p-MITF activity was quantified by luciferase activity. Results are the mean of three independent experiments, ±s.d.; *Po0.05 and **Po0.01.
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Hypoxia increases tumourigenic and metastatic potential of melanoma cells Finally, we studied the effect of hypoxic conditions on the tumourigenic and metastatic potential of B16 melanoma cells. After subcutaneous injection, melanoma cells exposed to hypoxia produced larger tumours, compared with their counterparts kept in normal oxygen conditions (Figure 6a ). Furthermore, when injected in the tail vein, hypoxia-exposed cells formed more lung tumours and visceral metastases (Figures 6b and c) . Therefore, exposure of melanoma cells to hypoxic conditions favours their tumourigenic and metastatic properties.
Discussion
In this study, we showed that MITF-depleted mouse and human melanoma cells have increased tumourigenic and metastatic potential in vivo when injected in mice. Furthermore, forced differentiation upon activation of the cAMP pathway by Forskolin and ablation of the MITF-negative population drastically reduced melanoma tumour and metastasis formation. Of course, Forskolin exerts pleiotropic biological effects in melanoma cells, including the inhibition of the PI3 kinase/ AKT/mTOR pathway and the activation of the ERK pathway (Busca and Ballotti, 2000) that can also participate in the reduction of the tumourigenic potential of melanoma cells. In addition, the antimelanoma action of Forskolin has been ascribed to a systemic effect of the compound (Agarwal and Parks, 1983) . Nevertheless, it should be noted that the PI3 kinase and ERK pathways converge to MITF. As MITF-forced expression in both mouse and human melanoma cells significantly reduces tumour formation, the anti-tumourigenic effect of Forskolin can be attributed, at least in part, to the removal of MITFnegative cells. One can also suggest that very high MITF expression, which might be induced by Forskolin, causes the inhibition of tumour growth (Wellbrock and Marais, 2005; Carreira et al., 2006) . However, it should be noted that fluorescence-activated cell sorting analysis of MITF expression in the tumours from mice treated with dimethyl sulfoxide or Forskolin (Supplementary Figure 2 ) showed an almost complete disappearance of the MITF-low population, strengthening the role of this population in the development of melanoma. Therefore, this approach which is reminiscent of the differentiation therapy used for leukaemia (Spira and Carducci, 2003) , may provide a pharmacological strategy to improve the treatment of metastatic melanoma, provided that they have a conserved cAMP pathway from adenylate cyclase to MITF.
Furthermore, MITF silencing in melanoma cells increased the expression of fibronectin and SNAI1 (SNAIL), which are markers of mesenchymal phenotype, and are key factors in the acquisition of metastatic properties (Alonso et al., 2007) . However, SNAI2 (SLUG), another mesenchymal marker, which also has a pivotal role in metastatic behaviour (Martin et al., 2005) , is downregulated in MITF-depleted cells. This observation can be explained by the fact that SNAI2 is a direct MITF target gene (Sanchez-Martin et al., 2002) . Of note, SLUG has been reported to be required for melanoma metastasis (Gupta et al., 2005) . In our hands, SLUG is not required for migration, invasion and metastasis. Overexpression of SNAIL might compensate for the loss of SLUG. In agreement with this hypothesis, in 501Mel human melanoma cells transfected with siMITF, we observed a loss of E-cadherin expression (not shown). SPARC, which has a key role in melanoma development (Ledda et al., 1997; Fenouille et al., 2011) and participates in the reinforcement of the mesenchymal phenotype (Robert et al., 2006) , is also clearly upregulated in MITF-depleted cells. These observations demonstrate that MITF silencing favours the mesenchymal phenotype, and acquisition of migration and invasion properties that can explain the increased 6 ) incubated for 24 h at 1% O 2 (hypoxia) or normal oxygen (Ct) were injected into the tail vein of mice. Seventeen days later, mice were killed and the number of lung tumours (b) or visceral metastases was counted and expressed as the mean ± s.e.m.; *Po0.05 and **Po0.01. metastasis development observed within the MITFdepleted cells. The mesenchymal phenotype was recently demonstrated to be linked to the acquisition of cancer stem cell properties (Mani et al., 2008) , and we recently showed that invalidation of MITF lead to an increase of stem cells markers, such as Oct4 and Nanog (Cheli et al., 2011) . Therefore, we conclude that MITF silencing generates the full spectrum of molecular responses that are required to generate melanoma-initiating cells with stem cell-like features.
Noteworthy, MITF depletion causes a G0/G1 arrest (Carreira et al., 2005; Giuliano et al., 2010) .Therefore, it appears that slow growing or arrested melanoma cells have an increased tumourigenic and metastatic potential. This apparent contracditory observation is perfectly in agreement with the report demonstrating that a slowgrowing population is required for melanoma development (Roesch et al., 2010; Cheli et al., 2011) . However, MITF was expressed in the smallest detectable tumours, even those arising from MITF-depleted cells (not shown). These observations support the phenotypeswitching hypothesis (Hoek et al., 2008; Hoek and Goding, 2010) , which suggests the existence of a reversible transition between invasive, slow-growing melanoma cells, and their more differentiated and fastgrowing progeny. The switch between the two phenotypes is controlled by MITF, the master gene in melanocyte differentiation.
The key question, then, was, how MITF is regulated within the melanoma tumours? Numerous extracellular signals, including WNT/DKK1, cAMP-elevating agents, endothelin, transforming growth factor-b and stem cell factor, regulate MITF expression. All of these agents can therefore modulate the number of MITF-low cells and thus the metastatic behaviour of the melanoma cells. However, one of the most frequent tumour conditions is hypoxia. Indeed, tumour regions, distant from supporting vasculature are hypoxic. We observed that exposure of melanoma cells to hypoxic conditions lead to an increase in HIF1a and a decrease in MITF expression. The hypoxia mimetic, CoCl 2 , inhibits MITF expression and decreases p-MITF activity. This effect is dependant on HIF1a, as small interfering RNA to HIF1a prevents the effect of hypoxia on both MITFand hypoxia-responsive promoters.
The key role of hypoxia and HIF1a in the regulation of MITF expression is strengthened by immunochemistry studies on human melanoma tumours, disclosing an inverse correlation between HIF1a and MITF expression in the perivascular region of two melanoma samples out of three. However, further studies, with a larger number of samples, are needed to assess the extent to which this phenomenon exists. Note that in agreement with this result, it has been reported that MITF showed a consistent anti-correlation with Glut1, a hypoxia marker, and a HIF1a target gene (Eichhoff et al., 2010) .
However, HIF1a overexpression is not sufficient to inhibit the p-MITF activity. The hypoxia-responsive element in the p-MITF is located between À1.5 and À2 kb from the transcription start site. This region does not contain an obvious HIF1a binding site (ACGTG), and ChIP experiment confirms that HIF1a does not bind to this p-MITF region strengthening the likelihood of an indirect effect of HIF1a on the p-MITF.
We identified Bhlhb2 (Bhlh40, Dec1, Stra13) as the mediator of hypoxic effect on MITF expression. Bhlhb2 was consistently upregulated under hypoxic condition, and Bhlhb2 knockdown prevents the decrease of MITF expression caused by hypoxia. Moreover, the À1.5 and À2 kb region of the p-MITF region contains three E-boxes that could bind Bhlhb2; one of these E-box is conserved in the mouse promoter. Bhlhb2 has a known transcriptional repression activity towards numerous target genes (Choi et al., 2008; Cho et al., 2009; Bhawal et al., 2011) . Bhlhb2 is involved in the control of circadian rhythms (Honma et al., 2002; Nakashima et al., 2008) , and has an anti-apoptotic activity (Ehata et al., 2007) . Our data will open new research avenue to investigate the role of this transcription factor in melanoma development.
Taken together, our data demonstrate that the loss of MITF initiated by hypoxia, is a pivotal event in the development of melanoma tumours and metastases. The effect of hypoxia may be due on one side to its proangiogenic action and on the other side to its prometastatic action on melanoma by favouring phenotype switching and acquisition of invasive properties.
Materials and methods
Cell culture B16-F10 mouse melanoma cells, and SkMel-28 human melanoma cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) supplemented with 7% foetal bovine serum (Invitrogen) and penicillin/streptomycin (100 IU/50 mg/ml (Invitrogen)). MeWo human melanoma cells were grown in RPMI medium 1640 (Invitrogen), with the same supplements. Cells were transfected with small interfering RNA against MITF (5 0 -r(GGUGGAUCGGAUCAUCAA GTT)d(TT)-3 0 ; Cheli et al., 2011) , small interfering RNA against Bhlhb2 (Dharmacon, Lafayette, CO, USA), small interfering RNA against Atf3 (Dharmacon), or a scrambled sequence using Lipofectamine RNAiMax (Invitrogen) according to the manufacturer's protocol as previously described (Cheli et al., 2011) . When indicated, cells were treated with cobalt (Sigma-Aldrich, St Louis, MO, USA) to mimic hypoxia. Hypoxic conditions were produced by incubation of cells in a Whitley H35 hypoxystation (Don Whitley Scientific, West Yorkshire, UK). The oxygen in this workstation was maintained at 1%, with the residual gas mixture being 93-94% nitrogen and 5% CO 2 . All media for the hypoxic experiment were buffered with 25 mM Hepes (Invitrogen).
Antibodies and reagents
Antibodies against Bhlhb2, Erk2, GAPDH, Hsp60, Snail and SLUG were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-fibronectin was from BD Biosciences (Franklin Lakes, NJ, USA). Anti-MITF (C5) was from Abcam (Pleasanton, CA, USA) and anti-HIF1a was from R&D systems (Minneapolis, MN, USA). Secondary alexa 488 was from Invitrogen. The HRE-LUC reporter vector contains three copies of the HRE from the erythropoietin promoter cloned upstream of a minimal thymidine kinase promoter and the luciferase reporter gene (Berra et al., 2003) . Human p-MITF cloned upstream of luciferase were previously described (Bertolotto et al., 1998) . The plasmid encoding a stabilised HIF1a mutant was a generous gift from Dr Pouysse´gure (Ginouves et al., 2008) . Flow cytometry was performed as previously described (Cheli et al., 2011) .
In vivo mouse tumour model Animal experiments were carried out in accordance with the Declaration of Helsinki Principles, and were approved by a Local Ethics Committee. Female immune-deficient athymic nude FOXN1 nu (nude) mice and C57BL6J mice were obtained at 6 weeks of age from Harlan Laboratory (Gannat, France). Animals were maintained in a temperature-controlled facility (22 1C) on a 12-h light/dark cycle, and were given free access to food (standard laboratory chow diet from UAR, Epinay-S/ Orge, France). Mice were inoculated subcutaneously with melanoma cells (0.25 Â 10 6 to 0.05 Â 10 6 B16 F10 cells per injection in 200 ml of phosphate-buffered saline). The growth tumour curves were determined by measuring the tumour volume using the equation
)/2 as previously described (Botton et al., 2009 ). Mice were killed by CO 2 inhalation, and tumours were removed and frozen for immunofluorescence study or analysed by western blot. The metastasis model was obtained by intravenous injection into the caudal vein of 0.25 Â 10 6 B16 F10 cells or 1 Â 10 6 MeWo per mouse in 100 ml of phosphate-buffered saline. Mice were treated with 82 mg Forskolin (Sigma-Aldrich; 4 mg/kg) by intraperitoneal injection 30 min before intravenous or subcutaneous cells injection, and Forskolin injection was repeated every 48 h. The growth tumour curves were determined by measuring the tumour volume during 15 days. Tumours were dissociated for 2 h with a mix of collagenase A (0.33 U/ml), Dispase (0.85 U/ml), DNase I (144 U/ml) in RPMI medium, and analysed by fluorescence-activated cell sorting as previously described (Cheli et al., 2011) .
Cell migration and invasion assay
The assay was carried out using the Cell Invasion and Migration Assay kit (Chemicon International, Temecula, CA, USA). Briefly, B16-F10 cells were transfected with 50 nM of small interfering RNA for 48 h. Cells (100 000) were added to each well in serum-free Dulbecco's modified Eagle's medium and allowed to migrate for 24-48 h at 37 1C in 5% CO 2 . The lower compartment of the chamber was filled with culture medium containing 7% fetal bovine serum. Cells at the lower membrane surface were fixed in 1% paraformaldehyde in phosphate-buffered saline (150 mM sodium phosphate, 154 mM sodium chloride, pH 7.2), stained with 0.1% crystal violet and counted (five random fields/well). Invasion assay was performed similarly as the migration assay, except that the upper chamber of the Transwell was coated with matrigel.
Western blot
Cells were solubilised for 10 min at 4 1C in buffer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100 and EDTA-free protease inhibitor cocktail from Roche Applied Science (Indianapolis, IN, USA). Then, 30 mg of proteins were separated by electrophoresis on 10% polyacrylamide SDS-PAGE and transferred onto a polyvinylidene fluoride membrane (Immobilon, Millipore, Molsheim, France). The membrane was blocked for 1 h at 25 1C in 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% Tween 20, 3% bovine serum albumin (weight/volume) and 5% gelatin (weight/volume). The primary antibody was incubated for 18 h at 4 1C. After three washes, each of 10 min, in 10 mM Tris, pH 7.4, 150 mM NaCl and 1% Triton X-100, the secondary antibody coupled with horseradish peroxidase (Dakopatts, Glostrup, Denmark) was then incubated for 1 h at 25 1C. After three additional washes, proteins of interest were revealed by enhanced chemiluminescence (Amersham, Uppsala, Sweden).
Reverse transcription and quantitative PCR Total cell RNA was extracted using the RNAeasy miniprep kit (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions, and 1 mg of RNA was reverse amplified using oligo dT, using the reverse transcription system (Promega, Madison, WI, USA) according to the manufacturer's instructions. PCR was performed using the StepOnePlus real-time PCR system and the power SYBR green PCR master mix reagent (Applied Biosystems, Foster City, CA, USA). Relative quantification of the amplicons was performed by 2(ÀDD C T ) method. Primer details are available upon request.
Chromatin immunoprecipitation assay B16F10 cells were cultured in 150-cm 2 culture dishes under normoxy, or treated with 200 mM of CoCl 2 for 18 h. Briefly, cells were fixed, collected and ChIP was carried out using EZ-ChIP Chromatin Immunoprecipitation Kit (Upstate, Jaffrey, NH, USA). After sonication, the sheared chromatin was immunoprecipitated using the indicated antibody. Then, the protein/DNA crosslinking complexes were reversed by heat treatment (65 1C overnight) and by proteinase K digestion. The genomic-captured fragments were purified using spin columns. Identification of the captured DNA fragments was performed by PCR analysis using the MITF or erythropoietin promoter primers (primer details available upon request). Thirty-five cycles of PCR were performed, and the amplified products were analysed on a 2% agarose gel.
Immunohistological staining
Tissue were fixed with 4% paraformaldehyde, permeabilised with 0.1% Triton-X 100 and stained with MITF-specific antibodies (C5, Abcam), or HIF1a (BD Bioscience). Antibodies were detected using the horseradish peroxidase-coupled antibody and revealed using Vectastain ABC kit form Vectorlabs (Burlingame, CA, USA).
Statistical analysis
Results are presented as means±s.d. or means±s.e.m. for the in vivo assay, with experiment numbers indicated in the figure legends. Statistical significance was assessed using the Student's t-test. Po0.05 was accepted as statistically significant.
